BioCryst lands European approval for flu treatment
Ahead of its planned merger with Exton, Pennsylvania-based Idera Pharmaceuticals, Durham ’s BioCryst Pharmaceuticals has landed European approval for its flu treatment.
BioCryst (Nasdaq: BCRX) said Tuesday that the European Medicines Agency has approved the treatment – an intravenous infusion in adults and children 2 years of age and older – under the brand name Alpivab.
“AL PIVAB approval in the European Union represents a significant advancement for influenza patients, representing the…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Jennifer Henderson Source Type: news
More News: Children | European Medicines Agency (EMA) | Health Management | Influenza | Mergers and Aquisitions